IbisVision

IbisVision is a Health Care startup founded in 2013, with the slogan "Early Detection of Glaucoma with Innovative Eye Test". The company has developed 'Ring of Sight' (ROS), an eye test geared towards the early detection of glaucoma. The condition is the second most common cause of blindness globally and poses a significant public health challenge. IbisVision's innovative solution aims to address this by facilitating early diagnosis, which is crucial given the irreversibility of detected damage. ROS leverages patented technology for visual field testing, employing a cursor and LED screen. The application, currently optimized for the Windows environment, features two main tests: the Full Threshold Test and the Suprathreshold Test. Notably, ROS is hosted remotely and utilizes advanced Cloud technology, allowing users to access it from any location. The company prioritizes data security and privacy, with all information stored on secure, encrypted servers. The company recently secured a significant £4.50M Venture Round investment on 11th May 2023, with participation from distinguished investors including Scottish Enterprise, Deepbridge Capital, and Compiler Venture Capital. This infusion of capital bodes well for IbisVision's growth and underscores investor confidence in the company's potential to make a meaningful impact in the field of eye health.